Literature DB >> 17999872

Aliskiren: the first direct renin inhibitor for hypertension.

Anton H van den Meiracker1, A H Jan Danser.   

Abstract

Aliskiren is the first member of a novel class of antihypertensive agents, the renin inhibitors, that has been approved by the US Food and Drug Administration for the treatment of hypertension. This review discusses its potential differences compared with existing renin-angiotensin-aldosterone system blockers, focusing also on the inactive precursor of renin, prorenin, and the recently discovered (pro)renin receptor. The review summarizes the findings from all clinical trials with aliskiren published so far, and provides an overview of the safety and tolerability of the new drug.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17999872     DOI： 10.1007/BF02938391

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  49 in total

1.  An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria.

Authors:  S Clausmeyer; R Stürzebecher; J Peters
Journal:  Circ Res       Date:  1999-02-19       Impact factor: 17.367

Review 2.  Local renin-angiotensin systems: the unanswered questions.

Authors:  A H Jan Danser
Journal:  Int J Biochem Cell Biol       Date:  2003-06       Impact factor: 5.085

3.  Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition.

Authors:  V Mooser; J Nussberger; L Juillerat; M Burnier; B Waeber; J Bidiville; N Pauly; H R Brunner
Journal:  J Cardiovasc Pharmacol       Date:  1990-02       Impact factor: 3.105

4.  Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations.

Authors:  J Itskovitz; J E Sealey; N Glorioso; Z Rosenwaks
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.

Authors:  Joep H M van Esch; Beril Tom; Vincent Dive; Wendy W Batenburg; Dimitris Georgiadis; Athanasios Yiotakis; Jeanette M G van Gool; René J A de Bruijn; René de Vries; A H Jan Danser
Journal:  Hypertension       Date:  2004-12-06       Impact factor: 10.190

Review 6.  Renin inhibition: what are the therapeutic opportunities?

Authors:  Naomi D L Fisher; Norman K Hollenberg
Journal:  J Am Soc Nephrol       Date:  2005-02-09       Impact factor: 10.121

7.  A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein.

Authors:  Jan H Schefe; Mario Menk; Jana Reinemund; Karin Effertz; Robin M Hobbs; Pier Paolo Pandolfi; Patricia Ruiz; Thomas Unger; Heiko Funke-Kaiser
Journal:  Circ Res       Date:  2006-11-02       Impact factor: 17.367

8.  Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.

Authors:  Byung-Hee Oh; Jerry Mitchell; James R Herron; Jenny Chung; Mahmudul Khan; Deborah L Keefe
Journal:  J Am Coll Cardiol       Date:  2007-03-20       Impact factor: 24.094

9.  Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy.

Authors:  A H Danser; M A van den Dorpel; J Deinum; F H Derkx; A A Franken; E Peperkamp; P T de Jong; M A Schalekamp
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

10.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Authors:  Y Huang; S Wongamorntham; J Kasting; D McQuillan; R T Owens; L Yu; N A Noble; W Border
Journal:  Kidney Int       Date:  2006-01       Impact factor: 18.998
View more
  3 in total

Review 1.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

2.  Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats.

Authors:  Elizabeth M Marchionne; Maggie K Diamond-Stanic; Mujalin Prasonnarong; Erik J Henriksen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-02       Impact factor: 3.619

Review 3.  The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure.

Authors:  Quanbin Xu; Dane D Jensen; Hua Peng; Yumei Feng
Journal:  Pharmacol Ther       Date:  2016-04-23       Impact factor: 12.310
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.